Last reviewed · How we verify

DYPHYLLINE

FDA-approved approved Small molecule Quality 0/100

Diphylline is a marketed drug with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and revenue generation. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic nameDYPHYLLINE
ModalitySmall molecule
PhaseFDA-approved
First approval1951

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results